ArticleWorld journal of clinical cases2022
Role of serum β2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels in diabetic nephropathy.
Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Close relationship between β2-microglobulin and type 2 diabetes-associated peripheral neuropathy.Journal of diabetes investigation · 2026Article
- Progression of early diagnostic markers for diabetic kidney disease: From single-indicator detection to multi-omics integration modeling.Current research in physiology · 2026Review
- Reliable biomarkers for diabetic nephropathy using machine learning-assisted contrast-enhanced ultrasonography and clinical characteristics.Clinical and experimental medicine · 2025Article
- Serum Behavior of NT-3 and VEGFβ, Two Unstudied Growth Factors in Patients with Diabetes Mellitus and End-Stage Renal Disease.Journal of clinical medicine · 2025Article
- A semantic segmentation method to analyze retinal vascular parameters of diabetic nephropathy.Frontiers in medicine · 2024Article
- Serum VEGF as a predictive marker of glycemic control and diabetic nephropathy in Chinese older adults with type 2 diabetes mellitus.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy (DN) is a common complication of type 1 and type 2 diabetes that can lead to kidney damage and high blood pressure. Increasing evidence support the important roles of microproteins and cytokines, such as β2-microglobulin (β2-MG), glycosylated hemoglobin (HbA1c), and vascular endothelial growth factor (VEGF), in the pathogenesis of this disease. In this study, we identified novel therapeutic options for this disease.
aimTo analyze the guiding significance of β2-MG, HbA1c, and VEGF levels in patients with DN.
methodsA total of 107 patients with type 2 diabetes mellitus complicated with nephropathy and treated in our hospital from May 2018 to February 2021 were included in the study. Additionally, 107 healthy individuals and 107 patients with simple diabetes mellitus were selected as the control groups. Changes in β2-MG, HbA1c, and VEGF levels in the three groups as well as the different proteinuria exhibited by the three groups were examined.
resultsChanges in β2-MG, HbA1c, and VEGF levels in the disease, healthy, and simple diabetes groups were significantly different (
conclusionThe expression of serum β2-MG, HbA1c, and VEGF was closely correlated with DN progression, and disease progression could be evaluated by these factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.